A dose ‐ranging study of ticagrelor in children aged 3–17 years with sickle cell disease: a two‐part phase 2 study

American Journal of Hematology,Volume 0, Issue ja, -Not available-.

Source: American Journal of Hematology - September 6, 2018 Category: Hematology Authors: Lewis L Hsu MD, PhD , Sharada Sarnaik MD , Suzan Williams MSc, MD , Carl Amilon PhD , Jenny Wissmar MSc , Anders Berggren MD, PhD , Source Type: research